Compare IVA & TROX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVA | TROX |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.2M | 680.2M |
| IPO Year | 2020 | 2005 |
| Metric | IVA | TROX |
|---|---|---|
| Price | $4.60 | $4.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 8 |
| Target Price | ★ $17.14 | $4.69 |
| AVG Volume (30 Days) | 228.7K | ★ 4.7M |
| Earning Date | 09-29-2025 | 02-11-2026 |
| Dividend Yield | N/A | ★ 4.66% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $19,929,536.00 | ★ $2,844,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.11 | $2.86 |
| 52 Week High | $7.98 | $10.60 |
| Indicator | IVA | TROX |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 52.04 |
| Support Level | $4.12 | $4.27 |
| Resistance Level | $4.58 | $4.57 |
| Average True Range (ATR) | 0.21 | 0.30 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 77.97 | 9.50 |
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.